TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$213.1 Million

Third Harmonic Bio, Inc.

Initial Public Offering

Bookrunner, September 2022

Third Harmonic Bio, Inc.

Third Harmonic Bio, Inc. (the “Company”) is a clinical-stage biopharmaceutical company focused on the development of the next wave of medicine for the treatment of allergic and inflammatory diseases. The Company’s lead product candidate, THB001, is a highly selective, oral small molecule inhibitor of KIT, a cell surface receptor that acts as the master survival and functional regulator of mast cells. KIT inhibition has shown promising clinical responses in mast cell mediated diseases such as asthma and chronic urticaria. The Company recently completed a Phase 1a clinical trial where THB001 demonstrated dose-dependent reductions of serum tryptase, a biomarker of cell activity which has been shown to correlate with clinical benefit in chronic urticaria patients. The Company is also exploring development opportunities across a range of other indications where mast cell driven inflammation can benefit from THB001’s product profile.